Emodin Protects against High-Fat Diet-Induced Obesity via Regulation of AMP-Activated Protein Kinase Pathways in White Adipose Tissue

Abstract

Emodin is an active herbal component traditionally used in China for treating a variety of diseases. The aim of this study was to examine the effect of emodin on the reducing lipid accumulation in white adipose tissue of high-fat diet-fed rats, and on the regulation of the expression of the genes involved in lipid metabolism to elucidate the mechanisms. After being fed a high-fat diet for two weeks, rats were dosed orally with emodin (20, 40, 80 mg/kg/day) or pioglitazone (20 mg/kg/day), once daily for eight weeks. Changes in body weight, feeding pattern, serum lipids, coronary artery risk index, and atherogenic index were investigated. Subcutaneous white adipose tissues were isolated for pathology histology and Western blot analyses. Changes of triglyceride accumulation in differentiated 3 T3-L1 adipocytes were also investigated. Emodin exhibited a significant concentration-dependent decrease in the intracellular accumulation of triglyceride in 3 T3-L1 adipocytes. Emodin (80 mg/kg/day) displayed similar characteristics to pioglitazone (20 mg/kg/day) in reducing body weight gain and plasma lipid levels as well as the coronary artery risk and atherogenic indices of high-fat diet-fed rats. Emodin also caused dose related reductions in epididymal white adipose tissue sizes in high-fat diet-fed rats. Emodin and pioglitazone enhanced the phosphorylation of AMP-activated protein kinase and its primary downstream targeting enzyme, acetyl-CoA carboxylase, upregulated gene expression of carnitine palmitoyl transferase 1, and downregulated sterol regulatory element binding protein 1 and fatty acid synthase protein levels in the epididymal white adipose tissue of high-fat diet-fed rats. Our findings suggest that emodin could attenuate lipid accumulation in white adipose tissue through AMP-activated protein kinase activation.

Key words

AMPK - emodin - high-fat diet - lipid - white adipose tissue

• References

• 1 Selassie M, Sinha AC. The epidemiology and aetiology of obesity: a global challenge. Best Pract Res Clin Anaesthesiol 2011; 25: 1-9
• 2 Karpe F, Dickmann JR, Fraynm KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60: 2441-2449
• 3 Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol 2011; 38: 1-10
• 4 Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005; 4: 1083-1095
• 5 Zheng CD, Duan YQ, Gao JM, Ruan ZG. Screening for anti-lipase properties of 37 traditional Chinese medicinal herbs. J Chin Med Assoc 2010; 7: 319-324
• 6 Chang CH, Lin CC, Yang JJ. Anti-inflammatory effects of emodin from Ventilago leiocarpa . Am J Chin Med 1996; 24: 139-142
• 7 Zhou M, Xu H, Pan L, Wen J, Guo Y, Chen K. Emodin promotes atherosclerotic plaque stability in fat-fed apolipoprotein E-deficient mice. Tohoku J Exp Med 2008; 215: 261-269
• 8 Hei ZQ, Huang HQ, Tan HM. Emodin inhibits dietary induced atherosclerosis by antioxidation and regulation of the sphingomyelin pathway in rabbits. Chin Med J 2006; 119: 868-870
• 9 Xue J, Ding W, Liu Y. Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010; 81: 173-177
• 10 Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 2008; 14: 539-549
• 11 Dong H, Lu FE, Gao ZQ, Xu LJ, Wang KF, Zou X. Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. World J Gastroenterol 2005; 11: 1339-1344
• 12 Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev 2000; 14: 1293-1307
• 13 Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab 2007; 32: 46-60
• 14 Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev 2010; 23: 270-299
• 15 Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi B, Graziano MP, Sybertz EJ, Strader CD, Davis Jr. HR. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997; 99: 385-390
• 16 Zhao XY, Qiao GF, Li BX, Chai LM, Li Z, Lu YJ, Yang BF. Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats. Clin Exp Pharmacol Physiol 2009; 36: 29-34
• 17 Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin 2005; 26: 575-580
• 18 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
• 19 Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein-cholesterol, total cholesterol screening and myocardial infarction. The Framingham Study. Arterosclerosis 1988; 8: 207-211
• 20 Shanmugasundaram KR, Visvanathan A, Dhandapani K, Srinivasan N, Rasappan P, Gilbert R, Alladi S, Kancharla S, Vasanthi N. Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight. Am J Clin Nutr 1986; 44: 805-815
• 21 Breuer HW. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin 2001; 17: 60-73
• 22 Trayhurn P. Adipocyte biology. Obes Rev 2007; 8: 41-44
• 23 Cowherd RM, Lyle RE, McGehee REJ. Molecular regulation of adipocyte differentiation. Semin Cell Dev Biol 1999; 10: 3-10
• 24 Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism–novel insights from genome-wide studies. FEBS Lett 2010; 584: 3242-3249
• 25 Björntorp P. Number and size of adipose tissue fat cells in relation to metabolism in human obesity. Metabolism 1971; 20: 703-713
• 26 Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am 2011; 95: 893-902
• 27 Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142?C: 77-85
• 28 Hagen RM, Rodriguez-Cuenca S, Vidal-Puig A. An allostatic control of membrane lipid composition by SREBP1. FEBS Lett 2010; 584: 2689-2698
• 29 Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011; 13: 376-388
• 30 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174